FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2218085405> ?p ?o ?g. }

• W2218085405 abstract "Dipeptidyl peptidase-4 (DPP-4) inhibitors have been shown to reduce hemoglobin A1c (HbA1c) in patients with type 2 diabetes, but the reduction varies between patients and adequate glycemic control may not be achieved. We evaluated the efficacy and safety of the DPP-4 inhibitor alogliptin in the real clinical setting, and analyzed factors associated with the improvement of HbA1c by alogliptin treatment.A retrospective observational study was performed in patients with type 2 diabetes attending hospitals or clinics belonging to the Kanagawa Physicians Association who received treatment with alogliptin for 1 year or longer. Patients using insulin were excluded from the study. The efficacy endpoints were HbA1c (National Glycohemoglobin Standardization Program value), blood glucose (fasting/postprandial), body weight, blood pressure (systolic/diastolic), liver function (glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, and γ-glutamyl transpeptidase), kidney function (serum creatinine and estimated glomerular filtration rate), serum lipids (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), and serum amylase. Adverse events were compiled to assess safety.Of 330 patients whose case records were collected, 27 patients were excluded for protocol violations, leaving 303 patients to form the full analysis set. Compared with baseline, HbA1c showed a decrease by 0.54±1.22% (mean ± standard deviation) after 12 months of alogliptin treatment. Factor analysis demonstrated that the change of HbA1c after 12 months was significantly influenced by the baseline HbA1c level, duration of diabetes, concomitant use of sulfonylureas, and compliance with diet therapy. In addition, there was a significant reduction of total cholesterol, low-density lipoprotein cholesterol, and the estimated glomerular filtration rate after 12 months of alogliptin treatment, as well as a significant increase in serum creatinine. No significant changes of body weight, blood pressure, or liver function were observed. Symptoms of hypoglycemia occurred in two patients (0.6%).Alogliptin displayed a significant hypoglycemic effect and excellent safety in routine clinical use. Factors influencing the change of HbA1c with alogliptin therapy may include the HbA1c at the start of treatment, the duration of diabetes, use of sulfonylureas, and compliance with diet therapy." @default.
• W2218085405 created "2016-06-24" @default.
• W2218085405 creator A5013194880 @default.
• W2218085405 creator A5013380810 @default.
• W2218085405 creator A5017515823 @default.
• W2218085405 creator A5021394857 @default.
• W2218085405 creator A5032756285 @default.
• W2218085405 creator A5035676969 @default.
• W2218085405 creator A5039351079 @default.
• W2218085405 creator A5047171102 @default.
• W2218085405 creator A5051480948 @default.
• W2218085405 creator A5052228923 @default.
• W2218085405 creator A5083517883 @default.
• W2218085405 date "2016-01-01" @default.
• W2218085405 modified "2023-09-25" @default.
• W2218085405 title "Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study" @default.
• W2218085405 cites W1967096313 @default.
• W2218085405 cites W1987019089 @default.
• W2218085405 cites W2023384663 @default.
• W2218085405 cites W2034667874 @default.
• W2218085405 cites W2047310345 @default.
• W2218085405 cites W2065185781 @default.
• W2218085405 cites W2074881344 @default.
• W2218085405 cites W2083190123 @default.
• W2218085405 cites W2092287139 @default.
• W2218085405 cites W2108324400 @default.
• W2218085405 cites W2123690908 @default.
• W2218085405 cites W2127854619 @default.
• W2218085405 cites W2140986962 @default.
• W2218085405 cites W2158693011 @default.
• W2218085405 cites W2161414118 @default.
• W2218085405 cites W92767927 @default.
• W2218085405 doi "https://doi.org/10.14740/jocmr2418w" @default.
• W2218085405 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4701069" @default.
• W2218085405 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26767082" @default.
• W2218085405 hasPublicationYear "2016" @default.
• W2218085405 type Work @default.
• W2218085405 sameAs 2218085405 @default.
• W2218085405 citedByCount "9" @default.
• W2218085405 countsByYear W22180854052016 @default.
• W2218085405 countsByYear W22180854052017 @default.
• W2218085405 countsByYear W22180854052019 @default.
• W2218085405 countsByYear W22180854052020 @default.
• W2218085405 countsByYear W22180854052021 @default.
• W2218085405 crossrefType "journal-article" @default.
• W2218085405 hasAuthorship W2218085405A5013194880 @default.
• W2218085405 hasAuthorship W2218085405A5013380810 @default.
• W2218085405 hasAuthorship W2218085405A5017515823 @default.
• W2218085405 hasAuthorship W2218085405A5021394857 @default.
• W2218085405 hasAuthorship W2218085405A5032756285 @default.
• W2218085405 hasAuthorship W2218085405A5035676969 @default.
• W2218085405 hasAuthorship W2218085405A5039351079 @default.
• W2218085405 hasAuthorship W2218085405A5047171102 @default.
• W2218085405 hasAuthorship W2218085405A5051480948 @default.
• W2218085405 hasAuthorship W2218085405A5052228923 @default.
• W2218085405 hasAuthorship W2218085405A5083517883 @default.
• W2218085405 hasBestOaLocation W22180854051 @default.
• W2218085405 hasConcept C126322002 @default.
• W2218085405 hasConcept C134018914 @default.
• W2218085405 hasConcept C156490143 @default.
• W2218085405 hasConcept C159641895 @default.
• W2218085405 hasConcept C160160445 @default.
• W2218085405 hasConcept C181199279 @default.
• W2218085405 hasConcept C185592680 @default.
• W2218085405 hasConcept C2777180221 @default.
• W2218085405 hasConcept C2778199505 @default.
• W2218085405 hasConcept C2779679107 @default.
• W2218085405 hasConcept C2780012697 @default.
• W2218085405 hasConcept C2780306776 @default.
• W2218085405 hasConcept C2780473172 @default.
• W2218085405 hasConcept C55493867 @default.
• W2218085405 hasConcept C555293320 @default.
• W2218085405 hasConcept C71924100 @default.
• W2218085405 hasConcept C90924648 @default.
• W2218085405 hasConceptScore W2218085405C126322002 @default.
• W2218085405 hasConceptScore W2218085405C134018914 @default.
• W2218085405 hasConceptScore W2218085405C156490143 @default.
• W2218085405 hasConceptScore W2218085405C159641895 @default.
• W2218085405 hasConceptScore W2218085405C160160445 @default.
• W2218085405 hasConceptScore W2218085405C181199279 @default.
• W2218085405 hasConceptScore W2218085405C185592680 @default.
• W2218085405 hasConceptScore W2218085405C2777180221 @default.
• W2218085405 hasConceptScore W2218085405C2778199505 @default.
• W2218085405 hasConceptScore W2218085405C2779679107 @default.
• W2218085405 hasConceptScore W2218085405C2780012697 @default.
• W2218085405 hasConceptScore W2218085405C2780306776 @default.
• W2218085405 hasConceptScore W2218085405C2780473172 @default.
• W2218085405 hasConceptScore W2218085405C55493867 @default.
• W2218085405 hasConceptScore W2218085405C555293320 @default.
• W2218085405 hasConceptScore W2218085405C71924100 @default.
• W2218085405 hasConceptScore W2218085405C90924648 @default.
• W2218085405 hasLocation W22180854051 @default.
• W2218085405 hasLocation W22180854052 @default.
• W2218085405 hasLocation W22180854053 @default.
• W2218085405 hasLocation W22180854054 @default.
• W2218085405 hasOpenAccess W2218085405 @default.
• W2218085405 hasPrimaryLocation W22180854051 @default.
• W2218085405 hasRelatedWork W1494558589 @default.
• W2218085405 hasRelatedWork W1521227597 @default.
• W2218085405 hasRelatedWork W1979438434 @default.

• next